CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Oncolytics Biotech Inc.

ONCY
$88MMicro Cap

Next catalyst

Phase 2Q3 2027

Pelareorep

Anal Cancer Metastatic

Get an email about ONCY's next catalysts

Track Oncolytics Biotech (ONCY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (conference, Phase 2 readout).See the timeline

Catalyst Timeline

3 upcoming, 1 past

Conference

Conference Presentation - pelareorep

Dec 12, 2026

For relapsed/refractory multiple myeloma. Oncolytics announced translational single-cell sequencing data from a Phase 1b/2 trial of pelareorep combined with bortezomib, dexamethasone, and pembrolizumab in heavily pretreated relapsed/refractory multiple myeloma patients, showing immune activation and tumor microenvironment remodeling. The data will be presented as a poster at the ASH Annual Meeting on December 12, 2026.

Source
Phase 2Next

Pelareorep Phase 2 Est. Readout (GOBLET)

Q3 2027~QPelareorep122

Primary completion for Pelareorep trial (NCT07280377) in Anal Cancer Metastatic

Source
Phase 2

Pelareorep Phase 2 Est. Readout

Q3 2027~QPelareorep60

Estimated primary completion for Pelareorep trial (NCT07446322) in Ras-mutated Metastatic Colorectal Cancer. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO28 employees

Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

Website

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Oncolytics Biotech Inc.'s drug pipeline?→

CatalystAlert tracks 10 drug candidates in Oncolytics Biotech Inc.'s (ONCY) pipeline across Phase 3, Phase 2. Its lead program is REOLYSIN (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Oncolytics Biotech Inc.'s next FDA catalyst?→

Oncolytics Biotech Inc.'s (ONCY) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ONCY biotech catalysts?→

Add ONCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Oncolytics Biotech Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply